TOKYO, JAPAN – February 9, 2023 – Terumo Corporation today announced that it will revise its performance evaluation system for executive officers, aligning executive compensation more closely with the company's long-term growth strategy and shareholder value creation.
The revised evaluation system is designed to strengthen the link between executive performance metrics and Terumo's medium- to long-term business objectives, including its 5-Year Growth Strategy "GS26."
"This revision reflects our commitment to strong corporate governance and ensuring that executive incentives are closely aligned with the sustainable growth of our business," said a Terumo representative. "We believe this evolved framework will further strengthen accountability at the executive level."
The updated performance evaluation system will take effect as part of Terumo's ongoing efforts to enhance its corporate governance practices.
About Terumo
Terumo (TSE: 4543) is a leading global provider of medical products and solutions with net sales of 4 billion USD. Founded in 1921, Terumo employs over 30,000 associates worldwide, and its products and services are available in more than 160 countries and regions. Terumo's stated mission is "Contributing to Society through Healthcare."
